The prognostic value and clinicopathological features of sarcomatoid differentiation in patients with renal cell carcinoma: a systematic review and meta-analysis
Authors Zhang L, Wu B, Zha Z, Zhao H, Feng Y
Received 27 February 2018
Accepted for publication 28 April 2018
Published 22 June 2018 Volume 2018:10 Pages 1687—1703
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Professor Nakshatri
Lijin Zhang, Bin Wu, Zhenlei Zha,* Hu Zhao,* Yejun Feng*
Department of Urology, Affiliated Jiang-Yin Hospital of the Southeast University Medical College, Jiang-Yin 214400, China
*These authors contributed equally to this work
Background and purpose: Numerous studies have demonstrated that sarcomatoid differentiation is linked to the risk of renal cell carcinoma (RCC). However, its actual clinicopathological impact remains inconclusive. Therefore, we undertook a meta-analysis to evaluate the pathologic and prognostic impacts of sarcomatoid differentiation in patients with RCC by assessing cancer-specific survival, overall survival, recurrence-free survival, progression-free survival, and cancer-specific mortality.
Materials and methods: In accordance with the preferred reporting items for systematic reviews and meta-analysis statement, relevant studies were collected systematically from PubMed, Embase, and Web of Science to identify relevant studies published prior to January 2018. The pooled effects (hazard ratios, odds ratios, and standard mean differences) and 95% confidence intervals were calculated to investigate the association of sarcomatoid differentiation with cancer prognosis and clinicopathological features.
Results: Thirty-five studies (N=11,261 patients [n=59–1,437 per study]) on RCC were included in this meta-analysis. Overall, the pooled analysis suggested that sarcomatoid differentiation was significantly associated with unfavorable cancer-specific survival (HR=1.46, 95% CI: 1.26–1.70, p<0.001), overall survival (HR=1.59, 95% CI: 1.42–1.78, p<0.001), progression-free survival (HR=1.61, 95% CI: 1.35–1.91, p<0.001), recurrence-free survival (HR=1.60, 95% CI: 1.29–1.99, p<0.001), and cancer-specific mortality (HR=2.36, 95% CI: 1.64–3.41, p<0.001) in patients with RCC. Moreover, sarcomatoid differentiation was closely correlated with TNM stage (III/IV vs I/II: OR=1.84, 95% CI: 1.12–3.03, p=0.017), Fuhrman grade (III/IV vs I/II: OR=8.37, 95% CI: 2.92–24.00, p<0.001), lymph node involvement (N1 vs N0: OR=1.88, 95% CI: 1.08–3.28, p=0.026), and pathological types (clear cell RCC-only vs mixed type: OR=0.48, 95% CI: 0.29–0.80, p=0.005), but was not related to gender (male vs female, OR=0.86, 95% CI: 0.58–1.28, p=0.464) and average age (SMD=−0.02, 95% CI: −0.20–0.17, p=0.868).
Conclusion: This study suggests that sarcomatoid differentiation in histopathology is associated with poor clinical outcome and advanced clinicopathological features in RCC and could serve as a poor prognostic factor for RCC patients.
Keywords: sarcomatoid differentiation, renal cell carcinoma, prognosis, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]